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Abstract
Background: Chronic obstructive pulmonary disease (COPD) patients often present considerable individual medical
burden in their symptoms, limitations, and well-being that complicate medical treatment. To improve their overall
health status, while reducing the number of exacerbations, a multidisciplinary approach including different elements of
care is needed. The aim of this study was to evaluate the effects of a remote support program on COPD patients at
high risk of experiencing worsening of their disease and other health-related outcomes.
Methods: An observational, multicenter, prospective study aimed at evaluating the impact of a 7-month remote
support program on COPD patients in exacerbations control and changes in health status measured with the COPD
assessment test (CAT). Factors associated with a clinically relevant decrease in CAT were assessed using a logistic
regression analysis.
Results: A total of 114 subjects started the program. The majority of the study population were males (81.6 %),
retired (70.2 %), without academic qualifications or with a low level of education (68.4 %), and ex-smokers (79.8 %). The
mean ± SD age was 69.6 ± 9.1 years and the BMI was 27.8 ± 5.5 Kg/m2. Overall, 41.9 % (95 % CI 31.9–52.0) patients,
significantly improved health status (CAT decrease ≥ 2 points). Univariate analysis showed that significant improvement
in CAT was associated with baseline CAT scores [high CAT score 19.2 (±7.5) vs. low CAT score 12.4 (±6.4); OR = 1.15,
95 % CI: 1.07–1.24; p < 0.001] and with being non-compliant [62.5 % (15/24) of non-compliant vs 34.7 % (24/69) of
compliant patients significantly improved CAT scores; OR = 3.13, 95 % CI: 1.19–8.19; p = 0.021). After controlling for the
effect of all variables in a multivariable logistic regression model, the only factor that remained significant was baseline
CAT score. The proportion of smokers in the total population remained constant during the study. There was a
significant reduction in the number of exacerbations after entering this remote support program with median -1
(IQR: -2, 0), (p < 0.001). The Morisky-Green questionnaire showed an increase of treatment compliance, namely at
baseline, 25.8 % (24/93) of patients were noncompliant while in the end 66.7 % (16/24) of them became compliant)
(p = 0.053).
Conclusions: A remote support program for high-risk COPD patients results in an improvement of the patients’
health status, particularly in those with initially poor health status, and it helps to reduce COPD exacerbations.
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Background
Chronic obstructive pulmonary disease (COPD) is consid-
ered a preventable, treatable, disabling respiratory disease
characterized by an often progressive and mainly irre-
versible airflow obstruction [1, 2]. COPD is currently
the fourth leading cause of death worldwide, and is pro-
jected to be the third cause of death in developed coun-
tries by 2020 [3, 4].
COPD is a paradigm of chronic disease, in which self-
management and support are essential for a proper con-
trol [5]. Primary medical management of COPD often
focuses on improving airflow using bronchodilators and
anti-inflammatory therapies; however, the airflow obstruc-
tion associated with COPD is not completely reversible
and often tends to progressively worsen over time [6].
Much of the deterioration and progression of the disease
is related to the number and severity of exacerbations ex-
perienced by patients [7] and, as the disease progresses,
the patients experience a worsening in their quality of
life [8]. Because complete recovery/cure from COPD is
impossible, health professionals should focus on the
improvement of patient-centered outcomes including
health status and quality of life; which are important
outcome measures for treatment and care in COPD pa-
tients [9].
Disease-specific programs are an integral component
of collaborative self-management. This approach is recog-
nized to improve health outcomes in people with chronic
conditions [10] and has also successfully improved the
health related quality of life (HRQoL) of patients with
chronic respiratory disease, such as asthma [11]. These
programs provide information for patients to recognize
and therefore to prevent, and decrease the severity and/or
frequency of symptoms and to implement appropriate
treatment for the episodes [11].
A number of studies have evaluated the effect of differ-
ent education programs for COPD and have concluded
that participation in these programs was associated with
an increase in the knowledge of COPD, an improvement
in specific skills to manage the disease, an increased ad-
herence to inhaled therapy, and a decrease in emer-
gency room visits and hospital admissions due to COPD
exacerbations; among other positive outcomes [12–15].
However, the available evidence is still inconclusive due to
different study designs, different types of COPD patients
included, methodological limitations, and a wide variation
of reported outcome measures.
We hypothesized that the implementation in a real
clinical practice setting of a disease-specific remote sup-
port program (Horizonte program) for COPD patients at
high risk, would positively influence these patients’ health
status. The Horizonte program basically consists of send-
ing text messages, e-mails, and conducting regular calls
by qualified nurses, to facilitate proper monitoring of
the disease (www.atlantishealthcare.com). It has been pre-
viously used in Spain under controlled conditions, to as-
sure its applicability in COPD patients, but has not been
incorporated in to common clinical practice until just
recently.
Thus, the primary aim of the study was to assess the
outcomes of the Horizonte remote support program for
COPD patients at high risk, in terms of reduction in fre-
quency and severity of exacerbations, and improvement
in the patients’ health status measured with the COPD
assessment test (CAT) when used as a part of the usual
treatment.
Methods
Design of the study and data collection
This was an observational, multicenter, prospective study
where 24 pulmonologists, distributed throughout the
Spanish national territory centres, recruited consecutive
patients between November 2013 and October 2014. Each
researcher aimed to recruit 9 consecutive patients.
Study population
Patients of both genders, aged 40 years or older, fulfilling
the selection criteria who signed the informed consent
were recruited. The inclusion criteria were: a) COPD
confirmed by spirometry performed in stable state not
more than 12 months prior to recruitment in the study
with a post-bronchodilator ratio of FEV1/FVC < 0.7; b)
smoker or former smoker of at least 10 pack-years; c)
patients with 2 or more moderate/severe exacerbations
reported in the 12 months prior to study entry; d) pa-
tient clinically stable at the time of inclusion in the study
and who was willing to participate in the Horizonte pa-
tient support program.
The exclusion criteria in the study were: (i) patients who
had never smoked, (ii) those who suffered a moderate/
severe exacerbation in the previous 30 days (iii) other
chronic respiratory disease (e.g. bronchial asthma, allergic
rhinitis, severe bronchiectasis, cancer, restrictive lung
disease, etc.) or pulmonary surgery, (iv) or who, in the
opinion of the investigator, did not demonstrate sufficient
cognitive capacity; presented sensory or psychiatric dis-
ability or language barriers that might prevent or hinder
participation in the study, (v) and participation in another
study or clinical trial.
An observation period of 12 months that included
7 months of allocation in the Horizonte remote support
program and a follow-up period of 5 months was estab-
lished. An evaluation was carried out before and after a
2 and 5-month period posterior to the inclusion in the
study, in which the effectiveness of the measures imple-
mented in the support program were assessed. Each patient
conducted their own self-monitoring, comparing their
health status sequentially. For each patient included,
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data was collected in an electronic data collection note-
book (e-CDR) designed for this purpose. The information
requested in this e-CDR conformed to usual clinical
practice, and referred to in the standard management
of patients with COPD.
Horizonte program
The Horizonte program (developed by the company At-
lantis Healthcare) (15) is based on the sending of text
messages (SMS) and e-mails, in addition to calls made
by skilled nurses, to patients who have given their con-
sent. The program has been endorsed by the Spanish
Pulmonology and Thoracic Surgery Society (SEPAR) and
it is a support program for patients with COPD and was
designed to help them understand their disease and treat-
ment by changing their misconceptions, improving adher-
ence to prescribed treatments and healthy habits (eg.
reducing smoking), and consequently their quality of life.
The program is available for both newly diagnosed COPD
patients and those already diagnosed and treated. Initially,
the risk of non-adherence is assessed in each patient by
the completion of a questionnaire. According to these
results, segments and risk levels are set (high or low
risk of non-adherence), and different interventions are
established: Telephone calls from nurses, notebooks in
which the objectives are preset to guide the patient,
magazines (5 issues for high risk and 2 issues for low
risk), additional documentation focused on the specific
problems of each patient (max. 4 per patient), and SMS
and e-mails whose frequency varies depending on the
patient’s risk (see a complete description at the end of
the manuscript).
The program’s objective is to improve patient educa-
tion with regard to the knowledge of their disease and to
achieve better adherence. Patient coordination is led by
the company Atlantis Healthcare and is funded by Takeda
Pharmaceutical Spain SA. A more detailed description of
the Horizonte program can be reviewed at Additional file 1.
Study variables
Recruiting physicians collected information regarding
demographic data, smoking, medical history, comorbidi-
ties, physical examination (weight, height, BMI, abdom-
inal circumference), pharmacological treatment, history
of exacerbations in the past 7 months, number of hospi-
talizations for COPD in the past 7 months, spirometry
(lung function), Morisky-Green and Levine Tests, Battle
test, exacerbations from baseline, and hospitalizations.
The cardiovascular risk was assessed according to BMI,
gender, and waist circumference [16].
Patients were asked to fill in the CAT questionnaire at
baseline (VB) and after 2 (V2), 7 (last Horizonte program
visit – V3) and 12 months (FV) in its validated Spanish
version. The CAT consists of 8 items with scores ranging
from 0 to 5 (0 = no impairment). An overall score is calcu-
lated by adding the score from each item with total scores
ranging from 0 to 40; a higher score indicates a more se-
vere health status impairment or a poorer control of
COPD [17, 18]. The CAT’s minimal clinical important
difference (MCID) has not yet been established, and
has been estimated to be 2.0 or more points [19].
“Moderate COPD exacerbations were defined as a sud-
den increase in respiratory symptoms that required am-
bulatory treatment with systemic corticosteroids and/or
antibiotics, and exacerbations were considered severe
when the patient required hospitalization”.
Sample size calculation
For the sample size calculation, it was estimated that
171 completers were needed to detect a mean change in
CAT of at least 2.5 (±10.0) points, with 90 % power and
an alpha of 0.05. Assuming a dropout rate of 20 % from
the start of the study, the number of patients recruited
should total 214.
Statistical analysis
To describe the qualitative variables, absolute frequencies
and percentages were used. For quantitative variables,
those normally distributed used mean, standard deviation
(SD), minimum and maximum figures, while median,
interquartile range, minimum and maximum were used
when they were not normally distributed.
Variables of interest were compared between study
groups using the Chi-squared or the Fisher’s exact test
for categorical variables, and the Student’s “t” test for
independent data (or the Mann-Whitney U test if the
assumption of normality was not met), to compare
quantitative variables. The Kolmogorov-Smirnov test or
Shapiro-Wilk test were used to assess if the quantitative
variables followed a normal distribution. Comparisons
of quantitative variables between more than two groups
were made using the Kruskal-Wallis test or analysis of
variance (ANOVA), depending on data distribution.
The pre and post-intervention comparisons of quantita-
tive variables were performed using the t Student test or
the Wilcoxon test, depending on the data distribution.
The pre and post-intervention comparisons of qualitative
variables of two categories were performed using the
McNemar test.
Incidence rates of exacerbations were described by annu-
alized incidence rates with their 95 % confidence interval
(95 % CI). Annualization of the rates and their correspond-
ing confidence intervals were performed by adjusting to a
Poisson model incorporating the time (expressed in years)
of each patient in the study as incidence rates with their
corresponding 95 % CI, and p-values. The analysis of a
clinically significant change in CAT was assessed by logistic
regression analysis, and expressed by the odds ratio (OR)
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with its 95 % confidence interval and p values. Changes in
CAT scores throughout the study were analyzed using a
generalized linear mixed model of repeated measures. Data
analysis was performed using the Statistical package SAS




The study flow-diagram and flow-chart are shown in
Figs. 1 and 2. A total of 148 subjects were initially recruited
in the study. Thirty-four were excluded because they did
not meet all the inclusion criteria (n = 114), then 100
completed the intervention program, and finally 93 com-
pleted all study procedures (62.8 %). Baseline demographic
characteristics of the patients are shown in Table 1. Most
participants were male (81.6 %) and were ex-smokers
(79.8). Mean age was 69.6 years ± 9.1 and mean BMI was
27.8 ± 5.5 Kg/m2. Clinical characteristics and pulmonary
function parameters of the sample at baseline are shown
in Tables 2 and 3, respectively. A total of 90 subjects
(78.9 %) had been vaccinated against influenza. Mean
FVC and FEV1 (%) at the baseline were 71.3 % (±19.4)
and 48.7 % (17.4 %) %, respectively. Regarding COPD
severity by spirometric GOLD stage, 5.3 % had mild
COPD, 36.8 % moderate, 43.9 % severe and 14.0 % very
severe COPD. At baseline, 98.2 % (112/114) of partici-
pating patients were receiving treatment/s for COPD
(Tables 1, 2 and 3)
Changes in smoking status and pharmacological
treatment
During the study, most participants (93.6 %) did not
change their smoking status. However, from baseline up
to 2 months prior to inclusion (V2), 4.3 % (4/93) of
participants changed their smoking status (2 gave up
smoking, one significantly decreased the number of
cigarettes/day, and another significantly increased the
Fig. 1 Flow Diagram of the study
Fig. 2 Flow-chart of the study
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Table 1 Socio-demographic characteristics of the study population
Overall Treatment non-adherence based on Morisky-Green baseline score
High-Risk Low-Risk p-value
N = 114 27 (23.7) 87 (76.3)
Gender
Men n(%) 93 (81.6) 18 (66.7) 75 (86.2) 0.043F
Women n(%) 21 (18.4) 9 (33.3) 12 (13.8)
Missing n 0 0 0
Age (years)
Mean (S.D.) 69.6 (9.1) 68.3 (10.0) 70.0 (8.8) 0.449U
≤ 65 years n(%) 44 (38.6) 11 (40.7) 33 (37.9) 0.793C
> 65 years n(%) 70 (61.4) 16 (59.3) 54 (62.1)
Missing n 0 0 0
Level of education
No studies/Primary studies n(%) 78 (68.4) 17 (63.0) 61 (70.1) 0.485C
Intermediate and higher education n(%) 36 (31.6) 10 (37.0) 26 (29.9)
Missing n 0 0 0
Employment situation
Retired n(%) 80 (70.2) 16 (59.3) 64 (73.6) 0.156C
Other n(%) 34 (29.8) 11 (40.7) 23 (26.4)
Missing n 0 0 0
BMI (kg/m2)
Mean (S.D.) 27.8 (5.5) 27.8 (6.2) 27.8 (5.3) 0.931U
Underweight (<18.5) n(%) 3 (2.6) 1 (3.7) 2 (2.3) 0.738F
Normal weight (18.5–24.9) n(%) 36 (31.6) 10 (37.0) 26 (29.9)
Overweight (25.0–29.9) n(%) 41 (36.0) 8 (29.6) 33 (37.9)
Obesity (≥30.0) n(%) 34 (29.8) 8 (29.6) 26 (29.9)
Missing n 0 0 0
Cardiovascular risk
None n(%) 31 (27.2) 8 (29.6) 23 (26.4) 0.907C
Increased n(%) 27 (23.7) 5 (18.5) 22 (25.3)
High n(%) 29 (25.4) 7 (25.9) 22 (25.3)
Very/Extremely high n(%) 27 (23.7) 7 (25.9) 20 (23.0)
Missing n 0 0 0
Smoking status
Ex-smoker n(%) 91 (79.8) 17 (63.0) 74 (86.1) 0.012C
Smoker n(%) 23 (20.2) 10 (37.0) 13 (14.9)
Missing n 0 0 0
COPD treatment (at baseline) n(%) 112 (98.2) 27 (100.0) 85 (97.7) 1.000C
Long-acting B2 agonists n(%) 101 (90.2) 23 (85.2) 78 (91.8) 0.456F
Long-acting anticholinergics n(%) 99 (88.4) 24 (88.9) 75 (88.2) 1.000F
Phosphodiesterase-4 Inhibitors n(%) 30 (26.8) 6 (22.2) 24 (28.2) 0.539C
Inhaled Corticosteroids n(%) 88 (78.6) 17 (63.0) 71 (83.5) 0.023C
Oxygen therapy n(%) 32 (28.6) 4 (14.8) 28 (32.9) 0.069C
non-invasive mechanical ventilation n(%) 12 (10.7) 4 (14.8) 8 (9.4) 0.479F
Missing n 0 0 0
COPD chronic obstructive pulmonary disease, S.D standard deviation, BMI body mass index
CChi-square test; FFisher’s exact test; UMann-Whitney U test
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number of cigarettes/daily). Between V2 and V3, 4.3 %
(4/93) of patients changed their smoking status, (2
gave up smoking, one resumed smoking again, and one
significantly reduced the number of cigarettes/day). Fi-
nally, between the V3 and FV, 2.2 % (2/93) of patients
significantly reduced the number of cigarettes/day.
During the baseline visit, COPD treatment was chan-
ged in 36.0 % (41/114) of patients. At the first follow-up
visit (V2), 99.1 % (111/112) of patients were receiving
treatment for COPD and during the visit; the treatment
was changed in 25.9 % (29/112) of them. At the last visit
of the program (V3) and at the end of the study (FV), all
patients were receiving treatment for COPD. Changes in
adherence are stated at the end of this section.
Changes in CAT
At baseline, patients had relatively high CAT scores:
[15.3 (SD = 7.6)]. Throughout the study period, CAT
scores improved an average of -0.4 (95 % CI: -1.6; 0.8)
points, although not statistically significant (p = 0.530,
paired t-Student) (Fig. 3). Worse health status measured
by CAT was associated with longer duration of COPD
(0.14 increase of CAT per year; p = 0.018), severe and
very severe GOLD stages (1.9 and 3.3 points more than
mild stages respectively; p = 0.015), higher scores in the
mMRC (6.2 points more in those with mMRC > 2) and
BODEx (5.4 points more in BODEx >4; p < 0.001), and
being a current smoker (2.3 increase compared with
ex-smokers; p = 0.026); whereas a better health status
measured by CAT was associated with higher FEV1(%)
(0.09 decrease per % unit; p < 0.001), longer walking au-
tonomy (2.9 and 5.2 points less than <30 min walkers
among those walking 30–60 min and > 60 min respectively;
p < 0.001) and higher compliance measured by the
Morisky- Green questionnaire (2.6 points less in com-
pliant patients; p = 0.005).
Significant Improvements in CAT
A total of 41.9 % (95 % CI 31.9–52.0) patients signifi-
cantly improved their reported health status (CAT de-
crease by 2 points or more). Univariate analysis showed
that significant improvement in CAT was associated with
baseline CAT scores [high CAT score 19.2 (±7.5) vs. low
CAT score 12.4 (±6.4); OR = 1.15, 95 % CI: 1.07–1.24;
p < 0.001] and being non-compliant as measured with
the Morisky-Green questionnaire [62.5 % (15/24) of
non-compliant vs 34.7 % (24/69) of compliant patients
significantly improved CAT scores; OR = 3.13, 95 % CI:
Table 2 Clinical characteristics
Overall Treatment non-adherence based on Morisky-Green baseline score
High-Risk Low-Risk p-value
N = 114 27 (23.7) 87 (76.3)
Time of evolution of COPD (years)
Mean (S.D.) 8.8 (6.8) 7.7 (6.2) 9.2 (7.0) 0.314U
Missing 1 0 1
Number of moderate exacerbations in the last 12 months
Mean (S.D.) 1.6 (1.1) 1.5 (0.8) 1.6 (1.2) 0.967U
Missing 0 0 0
Number of severe exacerbations in the last 12 months
Mean (S.D.) 1.2 (1.6) 0.7 (1.0) 1.4 (1.8) 0.049U
Missing 0 0 0
Total number of exacerbations in the last 12 months
Mean (S.D.) 2.8 (1.4) 2.2 (0.5) 3.0 (1.5) 0.003U
2–3 exacerbations n(%) 97 (85.1) 26 (96.3) 71 (81.6) 0.069F
4 or more exacerbations n(%) 17 (14.9) 1 (3.7) 16 (18.4)
Missing 0 0 0
Comorbidities
Cardiac comorbidities n(%) 41 (36.0) 8 (29.6) 33 (37.9) 0.432C
Coronary heart disease (CHD) n(%) 22 (19.3) 4 (14.8) 18 (20.7) 0.499C
Peripheral vascular disease n(%) 13 (11.4) 2 (7.4) 11 (12.6) 0.730F
Missing n 0 0 0
COPD chronic obstructive pulmonary disease, S.D standard deviation
CChi-square test; FFisher’s exact test; UMann-Whitney U test
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1.19–8.19; p = 0.021). After controlling for the effect of
all variables in a multivariable logistic regression model,
the only factor that remained associated with CAT change
(“significant improvement” vs. “no improvement”) was the
baseline CAT score (Table 4).
Change in the number of exacerbations
The average duration of COPD in the sample was 8.8 ±
6.8 years, while in the 12 months prior to the study,
85.1 % experienced 2 or 3 exacerbations and 14.9 % ex-
perienced 4 or more. During the Horizonte program
Table 3 Lung function at baseline
Overall Treatment non-adherence based on Morisky-Green baseline score
High-Risk Low-Risk p-value
N = 114 27 (23.7) 87 (76.3)
Spirometry
No n(%) 0 (0.0) ——— ———
Yes, prior to the visit n(%) 75 (65.8) 13 (48.2) 62 (71.3) 0.027C
Yes, during the visit n(%) 39 (34.2) 14 (51.8) 25 (28.7)
Spirometry results
FVC (ml) - Mean (S.D.) 2485.4 (844.0) 2546.7 (788.7) 2466.4 (864) 0.668T
FVC (%) - Mean (S.D.) 71.3 (19.4) 75.7 (21.7) 69.9 (18.6) 0.142U
FEV1 (ml) - Mean (S.D.) 1239.7 (521.8) 1456.3 (544.9) 1172.5 (498.7) 0.013T
FEV1 (%) - Mean (S.D.) 48.7 (17.4) 56.7 (17.8) 46.2 (16.6) 0.007U
FEV1/FVC (%) - Mean (S.D.) 50.8 (13.2) 57.3 (10) 48.8 (13.5) 0.004U
Missing n 0 0 0
GOLD stage
Stage I: Mild (80≤ FEV1%≤ 100) n(%) 6 (5.3) 2 (7.4) 4 (4.6) 0.074F
Stage II: Moderate (50≤ FEV1%≤ 79) n(%) 42 (36.8) 15 (55.6) 27 (31.0)
Stage III: Severe (30 ≤ FEV1%≤ 49) n(%) 50 (43.9) 7 (25.9) 43 (49.4)
Stage IV: Very severe (FEV1% < 30) n(%) 16 (14.0) 3 (11.1) 13 (14.9)
Missing n 0 0 0
O2 saturation (%)
X (D.E.) 93.9 (3.0) 95.0 (2.7) 93.5 (3.0) 0.025U
O2 saturation >90 % 98 (86.0) 25 (92.6) 73 (83.9) 0.351
F
Missing n 0 0 0
Minutes of walking per day
< 30 n(%) 39 (34.2) 6 (22.2) 33 (37.9) 0.323C
30–60 n(%) 36 (31.6) 10 (37.0) 26 (29.9)
> 60 n(%) 39 (34.2) 11 (40.7) 28 (32.2)
Missing n 0 0 0
Emphysema
No n(%) 56 (49.1) 18 (66.7) 38 (43.7) 0.037C
Yes n(%) 58 (50.9) 9 (33.3) 49 (56.3)
Missing n 0 0 0
BODEx index
Quartile 1: 0–2 points n(%) 28 (24.6) 12 (44.4) 16 (18.4) 0.011C
Quartile 2: 3–4 points n(%) 44 (38.6) 11 (40.7) 33 (37.9)
Quartile 3: 5–6 points n(%) 31 (27.2) 4 (14.8) 27 (31.0)
Quartile 4: 7–10 points n(%) 11 (9.6) 0 (0.0) 11 (12.6)
Missing n 0 0 0
S.D standard deviation
CChi-square test; FFisher’s exact test; TT-Test; UMann-Whitney U test
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(VB-V3), 45.0 % of patients experienced exacerbations
[30.0 % moderate exacerbations, 24.0 % severe exacerba-
tions (8.0 % exacerbations that led to emergency room
visits, and 17.0 % hospitalization)]. The median number
of exacerbations was 2 for total exacerbations (IQR 1-3)
with a maximum of 8; 1 for moderate exacerbation
(IQR: 1-2) with up to 6; 1 for severe exacerbation (IQR:
1-1) with up to 8; and 1 emergency exacerbation (IQR:
1-1) with a maximum of 5. After program completion,
57.0 % of patients had suffered exacerbations [35.5 %
moderate exacerbations, 29.0 % severe exacerbations,
(15.1 % emergency exacerbations, and 22.6 % exacerba-
tions requiring hospitalization)).
Changes in COPD exacerbations frequency 12 months
before and after the study are presented in Fig. 4. During
the 12 months before the study, median total exacerba-
tions was 2 (IQR: 2-3), while during the study it decreased
to 1 (IQR: 0-3). Median change (post-pre study) in the
number of exacerbations was therefore -1 (IQR: -2, 0),
(p < 0.001). For moderate exacerbations, patients expe-
rienced a median of 2 (IQR 1-2) and, during the study,
1 (IQR 0-1). Median change (post-pre study) in the number
of moderate exacerbations is -1 (IQR: -2, 0), (p < 0.001). Fi-
nally for severe exacerbations, patients experienced a
median previous exacerbations of 1 (IQR 0-2) and, dur-
ing the study, 0 (IQR 0-1), with a median change (post-
pre study) in the number of severe exacerbations of 0
(IQR: -1, 0), (p = 0.017).
Changes in pulmonary function
No significant differences in pulmonary function were
observed from baseline. Initial mean FVE1 was 49.5 %
(16.9) and at the end of the study it was 49.0 % (18.2) not
statistically significant (0.0 (IQR: -5.0; 4.0), p = 0.822).
Changes in adherence
Changes in adherence were of borderline significance
(p = 0.053). According to the Morisky-Green question-
naire, at baseline 25.8 % (24/93) of patients were non-
compliant. Of these patients, at the end of the study,
66.7 % (16/24) became compliant. Of the 74.2 % (69/93)
of compliant patients at baseline, 91.3 % (63/69) did not
change their adherence and 8.7 % (6/69) became non-
compliant when the study finished.
Discussion
The objective of the present study was to examine the
impact of a remote support program on the health status
of moderate/severe COPD patients. Recommendations
for the use of specific support programs for patients with
COPD are based on experience with other chronic dis-
eases such as diabetes [20], coronary artery disease [21],
and asthma [22]. Studies investigating the utility of such
programs for COPD reported heterogeneous conclusions,
and meta-analyses have argued that more studies are
needed [23, 24].
Reducing the burden of disease by improving patients’
symptoms, functional status, and quality of life are import-
ant goals. There has been a substantial increase in the use
of newly developed tools that measure health status and it
is important for clinicians and researchers to assess
these instruments’ strengths and weaknesses in provid-
ing insight into a patient’s condition and experience.
Relying only on mortality and physiological outcomes
could blind the clinician to the potential benefits that
patients may receive from a treatment. A growing body
of research utilizes end-points assessed directly by pa-
tients whose self-reported health status includes health-
related quality of life and their functional status [25].
Fig. 3 COPD assessment test (CAT) scores at baseline, at the first (V2) and second (V3) follow-up visits and at the end of the study (FV)
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The main finding of this study is that high risk COPD
patients; who received a remote support program based
on disease-specific self-management principles showed an
improvement in their health status in nearly half of the pa-
tients analyzed assessed with the CAT questionnaire and a
significant reduction in the occurrence of exacerbations.
Although we cannot identify which component of the
intervention had an effect, the results nevertheless re-
main important, considering the limitations of current
COPD treatments, the burden of the disease, and the
need for effective care plans to optimize the use of lim-
ited resources.
To assess health status in COPD patients, the most
widely used short questionnaires are CAT [18], the Clin-
ical COPD Questionnaire (CCQ) [26], the Airways Ques-
tionnaire 20 (AQ20) [27], and the COPD severity score
(COPDSS) [28]. In particular, CAT, AQ20, and CCQ have
been assessed on their predictive value for exacerbations
and mortality [29, 30]. CAT covers a broad range of effects
of COPD on patients’ health including cough, phlegm,
Table 4 Main objective analysis: Decrease in at least two points in CAT between the baseline and the final visit. Subgroup analysis:
univariate and multivariate models
Variable Category Univariate analysis
OR (CI 95 %)
Multivariate analysis




Age ≤65 years ——————
>65 years 0.48 (0.20–1.11)
BMI 1.00 (0.92–1.08)
BMI classification Normal (18.5–24.9) ——————
Overweight (25.0–29.9) 1.37 (0.49–3.82)
Obesity (≥30.0) 0.87 (0.31–2.49)
CAT 1.15 (1.07–1.24) 1.15 (1.07–1.24)
Time of evolution COPD (years) 0.96 (0.91–1.03)
Previous exacerbations 2–3 ——————
≥4 0.42 (0.11–1.65)
FEV1(%) Postbronchodilation 1.01 (0.98–1.03)
GOLD stage Mild-moderate ——————
Severe-very severe 0.96 (0.42–2.21)
Dyspnea ≤2 ——————
>2 0.67 (0.27–1.63)
BODEx index ≤4 ——————
>4 0.88 (0.38–2.07)
Minutes walking a day <30 ——————
30–60 1.48 (0.54–4.07)
>60 1.00 (0.36–2.78)
Morisky-Green questionnaire Compliant ——————
Noncompliant 3.13 (1.19–8.19)
Significant cardiac comorbidity No ——————
Yes 0.47 (0.17–1.36)
Cardiovascular risk None ——————
Increased 0.92 (0.28–3.102)
High 0.89 (0.27–2.89)
Very/extremely high 1.05 (0.33–3.38)
Smoking status Ex-smoker ——————
Smoker 1.98 (0.70–5.61)
COPD chronic obstructive pulmonary disease, BMI body mass index, CAT COPD Assessment Test
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chest tightness, breathlessness going up hills/stairs, ac-
tivity limitation at home, confidence leaving home,
sleep, and energy. CAT has demonstrated to be the best
predictive questionnaire for a series of outcomes (new
ambulatory or emergency exacerbations, hospitalization,
or death) in patients with moderate-to-severe COPD [31].
Some studies have shown that patients with severe
COPD improve less with specific health programs com-
pared with patients with less severe disease [32, 33].
Interestingly enough, our study suggests that non-
compliant patients and COPD patients with higher
CAT scores at baseline, which means a worse health
status, are the patients who have benefited the most
from this remote program. This could be explained, at
least partially, by differences in the severity of COPD
among these groups of patients which led to a better
health status and by the different interventions adapted to
each patient’s specific risk to non-adherence, with more
intense interventions for those patients at higher risk.
Duration of intervention has been demonstrated to be an
important variable in a previous meta-analysis [14]. The
health-related quality of life scores, COPD-related ED
visits, and hospital admission rates were similar between
groups during the initial 3- to 6-month follow-up. How-
ever, all of these outcomes reached statistical significance
when the program outcomes were compared after a
12-month follow-up. The 7-month duration of the
Horizonte program could have limited the statistical
significance of some outcomes.
Exacerbations are important determinants of prognosis
in patients with COPD, and are associated with health
status [34, 35], lung function [36], mortality [37], and
economic costs [38]. Prodromal symptoms of an exacer-
bation commonly occur up to a week before a discernible
reduction in lung function [39], and about one-half of
patients who seek treatment in an emergency depart-
ment report having had characteristic symptoms for at
least 4 days [40]. Early treatment of exacerbations has
been shown to reduce morbidity and effect on quality
of life [41] and the remote program implemented in the
study seems to be very effective at reducing exacerba-
tions, even in patients who are difficult to control and
with a long duration of COPD disease. Moreover, the
reduced number of exacerbation of the present study
confirms previous reports [42, 43] of improvements in
exacerbations with disease specific interventions. On the
contrary, in the study carried out by Van Wetering et al.,
no reductions in the number of exacerbations were ob-
tained [44]. This is probably associated with a less ad-
vanced COPD in the patients included in that study.
Adherence to treatment was obtained in 100 % of the
sample at the end of the program and it was maintained
until the end of the study, which could suggest an im-
provement in the compliance of the patients. Moreover,
the results of the Morisky-Green questionnaire showed
a tendency to an increase in adherence.
Regarding the impact of the program on smoking status,
significant heterogeneity has been observed in previous
studies assessing the impact of disease-specific education
programs. Only one out of three trials [45–47] reported
significant differences in the number of current smokers
between groups following the implementation of a
disease-specific education program, maybe due to the
fact that COPD patients lose their motivation after be-
ing discharged from the hospital, and supervised home-
based care could be more effective [48].
This approach of care through a continuum sup-
port and favouring self-management does not require
Fig. 4 Difference in the number of exacerbation (12 months before starting the study and during the 12-months follow-up of the study)
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specialized resources and can be easily implemented.
The present study supports its use as an integral part
of the long-term care of patients with moderate to
advanced COPD, but further studies are needed to
confirm their effectiveness.
Study limitations include lack of completion of the a
priori minimum sample size and those of any observa-
tional study, like neither randomization of the sample
nor reduced room for inferences. Additionally it would
have been desirable to have a control group to indetify
the effect of Horizonte program itself. Nevertheless, our
a priori defined recruitment procedure to minimize sam-
pling bias, systematic evaluation of consecutive COPD
patients from different centres, and evaluation of patients’
health status using a standardized assessment instrument
(CAT) strengthens our results. Our study characteristics
are very similar to those in COPD patients with frequent
exacerbations [14], so it is reasonable to assume that non-
included cases would have had similar characteristics.
Conclusions
The implementation of a remote support program for
high risk COPD patients results in improvements of
patients’ health status, particularly those with an ini-
tially poor health status, and it effectively reduces
exacerbations.
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